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began regulatory and commercial testing in
earlyApril, with sales to the public anticipat-
edfor the 1998-1999 flu season. Relenza, the
result of three decades' worth of research, is
what Tom Spurling, chief of the division of
molecular science at the Commonwealth
Scientific and Industrial Research
Organisation (CSIRO), headquartered in
Melbourne, Australia, calls "the world's first
antiviral drug for the treatment ofall strains
offlu."
The development ofthe new drug is the
result of a collaboration between Graeme
Laver, a visiting fellow at the John Curtin
School of Medical Research at Canberra's
Australian National University, CSIRO sci-
entist Peter Colman (now head of the
Biomolecular Research Institute [BRI] in
Melbourne), and a team ofinvestigators led
by Mark von Itzstein, head ofthe medicinal
chemistry department at Monash
University's Victorian College of Pharmacy
in Parkville, Australia. The scientists,
backed by the pharmaceutical companies
Biota Holdings and Glaxo Wellcome
Australia, have created a treatment that
appears to offer effective relief against the
annual scourge.
Relenza works by blocking the catalytic
activity ofthe enzyme neuraminidase-also
known as sialidase-on the influenza virus.
Neuraminidase helps in the spread ofinfec-
tion by releasing the flu virus from an
infected cell and allowing it to pass to adja-
cent healthy cells.
Laver's early work with the enzyme
includes a paper published in the May 1969
issue of Virology that first described the
morphology of the neuraminidase subunit
within the influenza virus. This led to using
the process of X-ray crystallography to
delineate the crystal structure of the
enzyme. Explains Colman, "X-ray crystal-
lography gives a hundred million-fold mag-
nification ofthe virus. It is a complex pro-
cedure, requiring sophisticated instrumen-
tation and computational facilities. And to
determine the crystal structure ofa protein,
first you need to isolate it, purify it, and
then crystallize it. None of these are trivial
tasks." In 1978, Laver successfully grew
neuraminidase crystals of a high enough
quality to begin the X-ray crystallography
process, and joined forces with Colman and
colleagues to map out the structure of the
enzyme. By 1987, Colman and colleagues
had fully identified the crystal structure of
neuraminidase.
At this point, Colman and colleague
Jose Varghese noticed a feature that they
came to realize is common to all flu strains:
a small "pocket" on the surface of the pro-
tein that is actually the active site of neu-
raminidase. The scientists realized that the
strain-invariant neuraminidase receptor site
might serve as a weak link that could be
exploited in order to treat influenza.
Working from Colman's lead, von Itzstein's
team was able to design and subsequently
synthesize the neuraminidase inhibitor that
is used in Relenza. Relenza works by plug-
ging the receptor pocket, thereby blocking
the catalytic activity of neuraminidase,
which prevents the flu from reproducing
and spreading.
At first, many researchers were doubtful
that the inhibitor would work, believing
that the incredibly fast rate at which flu
viruses can mutate and adapt to new hosts
meant it would be impossible to target all
strains of flu with one drug. But these
doubts have been allayed by the perfor-
mance of Relenza and other experimental
neuraminidase inhibitors being developed
around the world, such as GS4104, an oral-
ly administered drug developed jointly by
Gilead Sciences of Foster City, California,
and Hoffmann-La Roche of Nutley, New
Jersey, that has been shown to be effective
against influenza strains A and B in in vitro
clinical trials.
Relenza is delivered to the primary site
of infection, the lungs, as either a nasal
spray or asniffable powder. The medication
appears to work best when administered
within 30-36 hours of infection. When
taken soon after infection with influenza,
test subjects demonstrated a much shorter
duration of infection and blunted symp-
toms. Even high-risk patients in the studies,
such as the elderly and the immune-com-
promised, benefited from using Relenza.
Because the drug acts by stopping the
spread of the flu virus, it is less effective if
administered after flu symptoms begin to
appear. To counter this potential dilemma,
laboratories around the world are working
to develop simple, rapid diagnostic tests for
influenza that people can use at the doctor's
office or at home to determinewhether they
have been infected with the flu. Laver esti-
mates that some type ofhome rapid-detec-
tion kit may be available by the time
Relenza hits pharmacy shelves.
Given the flu's capacity for rapid shift-
ing, the question arises whether flu viruses
might mutate in such a way that the neu-
raminidase inhibitor would no longer be
effective. von Itzstein doesn't think so. "It is
possible that the virus can mutate upon
exposure to high doses of the drug [and]
work has been published on this already in
nonclinical studies," he says. "However, the
clinical relevance of this result is yet to be
determined. It is clear that if the virus sig-
nificantly alters its active site pocket, it may
well reduce its own infectivity." Colman
adds, "[Selection for mutation is] always a
possibility with any antiviral drug. Our
drug looks promising in the sense that resis-
tance is less likely than usual."
EPASPM2.5 Program Criticized
In May, the National Research Council
(NRC), the research arm of the National
Academy ofSciences, entered the debate over
the EPA's new air qualitystandard for partic-
ulate matter smaller than 2.5 microns in
diameter (PM2.5) by issuing a report that
strongly criticizes how the EPA has allocated
funds to study these air pollutants. The
report, which was requested by Congress,
states that the EPA is directing too many of
its resources toward monitoring concentra-
tions of the fine particles in air and toward
determining the sources ofthe pollution. On
the other hand, the report says, the EPA is
notdoing enough to investigatehuman expo-
sures, and its efforts to determinewhich types
of particulate matter are likely to harm
human health are"cruciallyinadequate."
The new National Ambient Air Quality
Standard for PM2.5 was set by the EPA in
July 1997, despite heavy opposition from
many industry groups. The goal of the law,
which supplements the EPA's standard for
particles less than 10 microns in diameter
(issued in 1987), is to protect thepublic from
the very small particles that can be inhaled
most deeply into the lungs. Several epidemio-
logical studies have found an association
between exposure to PM25 andserious health
problems including exacerbation ofasthma,
decreased lung function, respiratory diseases,
andprematuredeath.
The debate over the newPM2.5 standard,
however, centers on the fact that particulate
matter, the visible component ofsmoke and
haze, indudes awidevarietyofbothsolidand
liquid partides from diverse sources induding
forest fires, wind erosion, road construction,
and fossil fuel combustion. Little is known
about exactly which of these particles cause
health problems orbywhat biological mecha-
nisms they act. Business groups argued to the
EPA and Congress that the new PM2 stan-
dardwas unfairbecause industrieswou?d like-
ly bear the economic brunt ofthe regulation
despite a lack of evidence linking specific
sources or industries to the particles that
affecthealth.
Congress responded to the argument by
putting extra money in the EPA's 1998 bud-
get for filling the gaps in the science support-
ing the PM25 standard. Part of this money
was earmarked to fund a study ofthe EPA's
PM25 research and monitoring program, to
be completed by the NRC. Congress man-
dated that the NRC produce four reports on
PM25 research needs, of which the May
report, Research Priorities for Airborne
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ParticulateMatter, is the first.
In the report, the NRC criticizes the EPA
for allocating nearly one-third of its particu-
late matter budget for PM2.5 monitors that
will be used mostly to judge if areas are in
compliance with the new standard. Without
more information on how actual human
exposures relate to PM2.5 levels, and what
constituents or characteristics ofPM2.5 cause
health effects, the monitoring program may
fail to protect public health, the report says.
Noting thatthe EPAmonitoring methods are
known to miss some types ofparticles in their
measurements, the report states that the
NRC "recommends that EPA consider more
fully the possibility that the expensive moni-
toring program is not measuring the most
biologically important aspects of particulate
matter.
Officials within the EPA's particulate mat-
ter program call the NRC report useful, but
say that some of its criticisms are more the
result ofincomplete information than short-
comings on the EPA's part. "I would say that
from the comments in the report, there was
some confusion as to the magnitude ofsome
ofour projects," says John Vandenberg, assis-
tant director of the EPA's National Health
and Environmental Effects Research
Laboratory and the chiefcoordinator ofEPA
particulate matter research. "When they
looked at our resource allocations, they did
not take into account that we had been hold-
ingonto some resources in anticipation ofthis
report. Congress gave us around $23 million
above and beyond what we had requested for
particulate matter research.... Most of this
moneywe have held ontowhile wewaited for
[the NRC's] recommendation on where to
spend it." In the meantime, the EPA contin-
ued work on its monitoring program, says
Vandenberg, making it appear that monitor-
ingwasbeingdisproportionatelyfunded.
As for the usefulness of the particulate
matter monitoring program, John Bachman,
the associate director for science policy with
the EPA's Office ofAir Quality Standards
and Planning, says that, though it is well
known that the monitors may miss some par-
ticulates, it is also well known that the mass
measurements that they do take seem to be
related to health effects. "EPA's mandate is to
protect public health," says Bachman, "so we
would rather regulate something that we
knowcauses health problems, thoughwe may
not know which constituents are the prob-
lem, rather than wait until we have identified
the [health] effects of 10,000 different parti-
cles." However, he also emphasizes that the
EPA is setting up more highlysensitive moni-
tors that will give the agency information on
the constituents ofPM2.5.
Both Bachman and Vandenberg say that
the report will be helpful in plotting a course
for the EPA's particulate matter program.
"We are trying to be very responsive to the
[NRC]," says Vandenberg. "For example,
they said we were not researching exposures
enough, so we are now redirecting some
resources toward exposure assessment issues."
Industry groups that fought the EPA over
the new PM2 5 standard are not as satisfied
with the report, though it affirms some of
their accusations that the standard was based
on incomplete science. Theresa Larson, direc-
tor ofenvironmental quality for the National
Association of Manufacturers, one of the
industry groups that sued the EPA over the
standard, says that while the report makes
some good points, it will do little to help
industry. "The basiccomment [from industry
groups] is 'too little, too late,"' she says. "The
report sort ofhitwith a thud. Things are real-
ly too far along now for it to do any good.
Thestandards have already been set."
Besides pointing to immediate research
needs and suggesting that the EPA redirect
funding, the NRC report also recommends a
13-year, $444-million research program to
answer the remaining questions about PM25.
For the next few years, the NRC will work
with the EPA to help it define its particulate
matter research priorities, and the NRC com-
mittee that prepared the May report will
meet regularly with EPA scientists. The next
such meetingwill takeplaceJune 22-23.
Not Breathing Easier
Preservatives used in certain asthma medica-
tions may be doing more harm than good in
some patients. Researchers say
that the stabilizer edetate disodi-
um (EDTA) and the preservative
benzalkonium chloride (BAC),
which are commonlyusedinnebu-
lizer solutions for thetreatment of
asthma and chronic pulmonary
disease, actually counteract the
effects of the medications in
manypatients.
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Bad breath? New research shows that preservatives used in
asthma nebulizers may present a health risk to some people.
Approximately 15 million
people in the United States are
affected by asthma, 5 million of
whom are children, according to
the Department of Health and
Human Services. There was an
overall increase of 75% in the
number of cases of asthma
between 1980 and 1994, with an
increase of 160% among
preschool children for the same
period. Many researchers feel
there is a strong link between
environmental conditions and
the development ofasthma.
The treatment ofasthma usu-
ally involves two medication
options, according to Phillip Korenblat, apro-
fessor of clinical medicine at Washington
University in St. Louis, Missouri, and a
spokesman for the American College of
Allergy, Asthma, and Immunology-rapid
relievers, or bronchodilators, and long-term
controllers. Korenblat says that asthma
patients should keep a rapid reliever available
atall times in the case ofan asthmaattack, but
theyshould not rely on such a medication for
long-term treatment. There are two types of
bronchodilators-multidose inhalers, which
administer medicine by means ofa propellant
or drypowder, and nebulizer solutions, which
are delivered byan air compressor in the form
of a spray designed to be inhaled. Korenblat
says a very small minority ofasthma patients
use the nebulizer solutions. However, they are
often administered to patients in hospitals and
in emergencysituations.
An article by asthma researchers at the
Wellington College of Medicine in New
Zealand and the University of Florida in
Gainesville, published in theJanuary-February
1998 issue ofPharmacotherapy, offers X review
ofstudies conducted on nebulizer solutions
both with and without the preservatives. The
preservatives BAC and EDTA are added to
nebulizer solutions that are dispensed in mul-
tidose dropper bottles andunit-dose screw-cap
products in order to keep them sterile. The
medications contained in nebulizer solutions
are designed to open the bronchial tubes lead-
ing to the lungs, but the authors contend that
at standard doses BAC constricts these air-
ways, working against the medications and
sometimes worsening the lung function in
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